Pathogenesis and treatment of chronic myeloid leukemia: current status

VernacularTitle:慢性粒细胞白血病的发病机制及治疗现状
Author: Peng CHEN
Publication Type:Journal Article
Keywords: Leukemia,myelogenous,chronic; Tyrosine kinase inhibitors; bcr-abl
From: Journal of Leukemia & Lymphoma 2016;25(8):509-512
CountryChina
Language:Chinese
Abstract: Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease,which originates from multifunctional hematopoietic stem cells of bone marrow.Imatinib is used as the first-line treatment for CML currently,owing to its obvious curative effect for patients in chronic phase and survival time prolonged significantly for patients in accelerated phase and blast crisis.With the long-term application of imatinib in clinic,the drug resistance and intolerance gradually appear,resulting in decreased long-term effects of CML.This paper will review the current status of the pathogenesis and treatment of CML.